布洛芬与肾损伤:研究揭示高风险患者群体
Ibuprofen and Kidney Injury: Study Reveals Who Is Most at Risk
一项回顾性队列研究发现,布洛芬与住院成人急性肾损伤(AKI)风险增加相关,但主要集中在术后和重症患者。年轻且肾功能正常的低风险患者使用布洛芬不增加AKI风险。研究结果提示需对患者进行风险分层,以优化镇痛治疗。
研究揭示了使用布洛芬导致急性肾损伤的风险主要集中在特定患者群体,有助于优化住院患者的镇痛治疗。
— Higher AKI risk seen only in certain patients
November 11, 2026 • 3 min read
- Fear of acute kidney injury may limit inpatient NSAID use, driving reliance on opioids for acute pain despite dependency risks.
- Compared with oxycodone, ibuprofen was linked to a higher rate of acute kidney injury among hospitalized adults in a retrospective cohort study.
- However, this excess risk was primarily seen in critically ill and postoperative patients.
Use of ibuprofen was associated with higher rates of acute kidney injury (AKI) among hospitalized adults, but the excess risk was concentrated almost entirely in certain patients, according to a retrospective active-comparator cohort study.
Compared with patients given oxycodone for acute pain, those who received at least 24 hours of ibuprofen had higher adjusted rates of the following:
- Any AKI: incidence rate ratio (IRR) 1.22, 95% CI 1.09-1.38
- Severe AKI: IRR 1.36, 95% CI 1.08-1.72
- Initiation of kidney replacement therapy (KRT): IRR 3.29, 95% CI 1.35-8.03
The heightened risk was driven primarily by high-risk populations: postoperative patients (IRR 1.70, 95% CI 1.28-2.27) and critically ill patients in the intensive care unit (IRR 1.65, 95% CI 1.29-2.11), reported Todd Miano, PharmD, PhD, of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues.
In contrast, patients deemed low risk -- those younger than 60, not critically ill, not recovering from surgery, and with preserved baseline kidney function (estimated glomerular filtration rate >60 mL/min/1.73 m²) -- had no elevated AKI risk associated with ibuprofen use (IRR 0.94, 95% CI 0.75-1.18).
These findings "suggest that there may be a subset of patients who can safely be treated with NSAIDs [nonsteroidal anti-inflammatory drugs], such as younger patients with preserved kidney function who are not critically ill and are not postoperative," the authors wrote in JAMA Network Open.
However, current hospital practice did not appear to reflect that distinction. Even among low-risk patients in the study, 87% were prescribed oxycodone over ibuprofen.
"NSAIDs cause nephrotoxic effects, primarily through vasoconstriction of afferent arterioles in the glomerulus, which can reduce kidney blood flow, leading to ischemic AKI in vulnerable patients," Miano and team explained. "Most evidence regarding NSAID-AKI risk comes from outpatient settings, where patients often use NSAIDs for extended durations. In contrast, hospitalized patients typically receive NSAIDs for at most a few days."
While low-risk patients may safely tolerate ibuprofen, they "are often prescribed oxycodone," which carries an "extensive adverse-effect profile" and risks long-term dependence, the authors emphasized. "Thus, our analysis suggests that outcomes might be improved with enhanced risk stratification and individualized analgesic prescribing that effectively identifies patients at low risk of NSAID-associated AKI."
For this study, the researchers reviewed records for 78,656 hospitalized adults admitted to three Philadelphia hospitals within the University of Pennsylvania Health System from January 2004 through June 2017. Patients with end-stage kidney disease, baseline serum creatinine over 2.0 mg/dL, recent unresolved AKI, or other contraindications were excluded. Median patient age was 59, 48% were women, 59% were white, and 31% were Black.
Overall, 72,343 patients received oxycodone and 6,313 received ibuprofen. In the unweighted raw data, inpatients given ibuprofen were younger (median age 52 vs 59 years), had fewer comorbidities, and had a lower crude AKI rate (5.1% vs 6.2%) than those given oxycodone. Median follow-up was 3.0 days.
Over 270,472 days of patient follow-up, 4,799 AKI events occurred (17.7 events per 1,000 days). AKI was defined by changes in serum creatinine and initiation of KRT according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria and staged over 7 days after onset. Most AKI events were stage 1 (79%), 15% were stage 2, and 6% were stage 3.
In a post-hoc subgroup analysis, the IRR of AKI was 1.48 (95% CI 1.18-1.86) among patients with concomitant nephrotoxin exposure and 1.15 for those without such exposure (95% CI 1.00-1.32).
The authors noted that prescribing decisions cannot hinge on nephrotoxicity alone. "While our analysis was focused on kidney outcomes, other NSAID-mediated adverse effects (e.g., bleeding) also inform prescribing decisions," they wrote. "Research evaluating the broader comparative safety of these classes is needed to optimize inpatient analgesia."
Patients who received both ibuprofen and oxycodone on the index date were excluded, which may limit generalizability to those treated with both drugs.
来源:MedPage Today · medpagetoday.com